Pelatro PLC (LON:PTRO) is a software provider focussed on the telecom sector, offering telecom operators...
08.23 Mon 27 Jul 2020
Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only...
TomCo (LON:TOM) is an oil & gas exploration and production company which, operates in the...
Revive Therapeutics (CSE:RVV, OTCQB:RVVTF) is a speciality life sciences company focussed on...
Eco Equity has established a unique position within the fast-growing market for legal cannabis....
Primary Health Properties (LON:PHP) recently announced interim results for the period to June...
Location Sciences (LON:LSAI), the world leader in location verification for mobile advertising,...
MXCT made outstanding progress in H1 20 across the business and is set to report revenue growth...
MaxCyte’s new clinical and commercial licence agreement with Apeiron Biologics allows the...
Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number...
